vs
Aardvark Therapeutics, Inc.（AARD）与AbCellera Biologics Inc.（ABCL）财务数据对比。点击上方公司名可切换其他公司
Aardvark Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对炎症、代谢类疾病及罕见病的新型靶向疗法，核心管线聚焦G蛋白偶联受体相关药物，主要服务北美及全球患者群体，开展医药研发领域合作。
AbCellera Biologics是一家总部位于不列颠哥伦比亚省温哥华的生物科技企业，核心业务是探索与开发抗体治疗药物。该公司凭借 proprietary 技术平台可在60天内开发出医疗应对方案，其单细胞筛选技术平台最早诞生于不列颠哥伦比亚大学，还曾作为核心力量参与美国国防高级研究计划局的大流行预防平台项目。
AARD vs ABCL — 直观对比
营收规模更大
ABCL
是对方的Infinity倍
$0
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $44.9M |
| 净利润 | $-17.6M | $-8.9M |
| 毛利率 | — | — |
| 营业利润率 | — | -63.7% |
| 净利率 | — | -19.9% |
| 营收同比 | — | 788.4% |
| 净利润同比 | — | 73.9% |
| 每股收益（稀释后） | $-0.81 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AARDABCL
| Q4 25 | $0 | $44.9M | ||
| Q3 25 | $0 | $9.0M | ||
| Q2 25 | $0 | $17.1M | ||
| Q1 25 | $0 | $4.2M | ||
| Q4 24 | — | $5.0M | ||
| Q3 24 | — | $6.5M | ||
| Q2 24 | — | $7.3M | ||
| Q1 24 | — | $10.0M |
净利润AARDABCL
| Q4 25 | $-17.6M | $-8.9M | ||
| Q3 25 | $-16.3M | $-57.1M | ||
| Q2 25 | $-14.4M | $-34.7M | ||
| Q1 25 | $-9.3M | $-45.6M | ||
| Q4 24 | — | $-34.2M | ||
| Q3 24 | — | $-51.1M | ||
| Q2 24 | — | $-36.9M | ||
| Q1 24 | — | $-40.6M |
营业利润率AARDABCL
| Q4 25 | — | -63.7% | ||
| Q3 25 | — | -851.8% | ||
| Q2 25 | — | -290.2% | ||
| Q1 25 | — | -1479.6% | ||
| Q4 24 | — | -1441.0% | ||
| Q3 24 | — | -1439.4% | ||
| Q2 24 | — | -1276.2% | ||
| Q1 24 | — | -551.5% |
净利率AARDABCL
| Q4 25 | — | -19.9% | ||
| Q3 25 | — | -637.8% | ||
| Q2 25 | — | -203.3% | ||
| Q1 25 | — | -1077.2% | ||
| Q4 24 | — | -677.6% | ||
| Q3 24 | — | -785.4% | ||
| Q2 24 | — | -504.3% | ||
| Q1 24 | — | -408.0% |
每股收益（稀释后）AARDABCL
| Q4 25 | $-0.81 | $-0.03 | ||
| Q3 25 | $-0.75 | $-0.19 | ||
| Q2 25 | $-0.66 | $-0.12 | ||
| Q1 25 | $-0.71 | $-0.15 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.17 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.0M | $128.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $106.6M | $966.9M |
| 总资产 | $117.2M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AARDABCL
| Q4 25 | $110.0M | $128.5M | ||
| Q3 25 | $126.3M | $83.2M | ||
| Q2 25 | $141.8M | $92.4M | ||
| Q1 25 | $151.3M | $159.3M | ||
| Q4 24 | — | $156.3M | ||
| Q3 24 | — | $126.6M | ||
| Q2 24 | — | $148.3M | ||
| Q1 24 | — | $123.6M |
股东权益AARDABCL
| Q4 25 | $106.6M | $966.9M | ||
| Q3 25 | $122.4M | $964.0M | ||
| Q2 25 | $136.9M | $1.0B | ||
| Q1 25 | $150.7M | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
总资产AARDABCL
| Q4 25 | $117.2M | $1.4B | ||
| Q3 25 | $133.2M | $1.4B | ||
| Q2 25 | $147.5M | $1.4B | ||
| Q1 25 | $157.0M | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.8M | $-34.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-44.6M |
| 自由现金流率自由现金流/营收 | — | -99.4% |
| 资本支出强度资本支出/营收 | — | 21.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-174.1M |
8季度趋势，按日历期对齐
经营现金流AARDABCL
| Q4 25 | $-16.8M | $-34.7M | ||
| Q3 25 | $-16.1M | $-52.6M | ||
| Q2 25 | $-9.8M | $-32.4M | ||
| Q1 25 | $-11.4M | $-11.6M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $-28.9M | ||
| Q2 24 | — | $-30.0M | ||
| Q1 24 | — | $-41.7M |
自由现金流AARDABCL
| Q4 25 | — | $-44.6M | ||
| Q3 25 | $-16.1M | $-61.5M | ||
| Q2 25 | $-9.9M | $-45.8M | ||
| Q1 25 | — | $-22.2M | ||
| Q4 24 | — | $-23.6M | ||
| Q3 24 | — | $-47.4M | ||
| Q2 24 | — | $-50.1M | ||
| Q1 24 | — | $-65.8M |
自由现金流率AARDABCL
| Q4 25 | — | -99.4% | ||
| Q3 25 | — | -687.0% | ||
| Q2 25 | — | -267.9% | ||
| Q1 25 | — | -524.0% | ||
| Q4 24 | — | -468.0% | ||
| Q3 24 | — | -728.4% | ||
| Q2 24 | — | -683.8% | ||
| Q1 24 | — | -661.5% |
资本支出强度AARDABCL
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 99.7% | ||
| Q2 25 | — | 78.2% | ||
| Q1 25 | — | 251.1% | ||
| Q4 24 | — | 309.6% | ||
| Q3 24 | — | 284.6% | ||
| Q2 24 | — | 274.6% | ||
| Q1 24 | — | 242.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
